TOVXTheriva Biologics, Inc.

NYSE therivabio.com


$ 0.39 $ 0.00 (-0.88 %)    

Friday, 17-May-2024 08:27:45 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 0.3707
$ 0.39
$ 0.00 x 0
$ 0.00 x 0
$ 0.39 - $ 0.39
$ 0.20 - $ 1.20
36,012
na
6.36M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-16-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-20-2020 12-31-2019 10-K
19 11-04-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-01-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 03-02-2017 12-31-2016 10-K
31 11-01-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 theriva-biologics-to-discuss-the-trial-design-for-virage---a-phase-2b-clinical-study-of-systemically-administered-vcn-01-in-combination-with-chemotherapy-in-pancreatic-ductal-adenocarcinoma-at-the-2024-asco-annual-meeting

Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and relat...

 theriva-biologics-to-present-preclinical-data-for-potential-synergy-of-vcn-01-and-first-line-pancreatic-cancer-chemotherapy-regimens-at-american-society-for-cell-and-gene-therapy-27th-annual-meeting

– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human p...

 theriva-biologics-fy-eps-114-beats-128-estimate-as-of-december-31-2023-theriva-biologics-reports-232m-in-cash-which-is-expected-to-provide-runway-into-the-first-quarter-of-2025

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.2...

 earnings-scheduled-for-march-25-2024

Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on re...

 theriva-biologics-granted-eu-patent-3292142-for-oncolytic-adenoviruses-with-mutations-in-immunodominant-adenovirus-epitopes-and-their-use-in-cancer-treatment

https://data.epo.org/publication-server/pdf-document?pn=3292142&ki=B1&cc=EP

 theriva-biologics-announces-positive-recommendation-from-the-independent-data-monitoring-committee-of-virage-the-phase-2b-clinical-trial-of-vcn-01-in-combination-with-chemotherapy-for-metastatic-pancreatic-ductal-adenocarcinoma

Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and relat...

 theriva-biologics-q3-eps-019-beats-038-estimate-312m-in-cash-which-is-expected-to-provide-runway-into-the-first-quarter-of-2025

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.3...

 earnings-scheduled-for-november-13-2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr...

 theriva-biologics-announced-new-clinical-data-from-phase-1-investigator-sponsored-study-with-institut-catala-doncologia-evaluating-vcn-01-in-combination-with-durvalumab

These data were presented at the European Society for Medical Oncology (ESMO) Congress, held both virtually and in Madrid, Spai...

 theriva-biologics-announces-presentation-at-esmo-congress-2023-featuring-survival-outcomes-in-phase-1-study-evaluating-vcn-01-in-combination-with-durvalumab-in-patients-with-recurrentmetastatic-squamous-cell-carcinoma-of-the-head-and-neck

-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patien...

 theriva-biologics-q2-eps-034-down-from-031-yoy-cash-bal-342m

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.34) per share. This is a 9.68 percent decrease over losses of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION